On-Demand Plerixafor With Cyclophosphamide And G-Csf For Hematopoietic Stem-Cell Mobilization In Multiple Myeloma Patients: Preliminary Results Of A Prospective Observational Study (Mozobl06877)

Background. High-dose melphalan followed by autologous stem cell transplantation is a standard of care in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients and is also an option at relapse. Therefore, since the minimum number of CD34+ cells required to ensure adequate bone marrow recovery after myeloablative chemotherapy is 2x10^6/kg, an adequate upfront stem-cell collection is necessary in MM patients. Approximately 5-15% of MM patients mobilized with granulocyte colony-stimulating factor (G-CSF) or G-CSF+cyclophosphamide (G-CSF/CY) fail stem-cell collection (<2x10^6/kg CD34+). Plerixafor in combination with G-CSF or G-CSF/CY increases stem-cell yield and lowers the rate of poor mobilizers (PM). Here we present preliminary results of the prospective, observational MOZOBL06877 study (partially supported by Sanofi investigation funds) to evaluate the performance of stem-cell mobilization with G-CSF/CY plus on-demand plerixafor in NDMM patients treated with novel agents.